SMITH & NEPHEW PLC ORD USD0.20
Symbol: SN.
Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Charts
Company
Business Summary
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
Financial Summary
BRIEF: For the fiscal year ended 31 December 2023, Smith & Nephew plc revenues increased 6% to $5.55B. Net income increased 18% to $263M. Revenues reflect Sports Medicine & ENT segment increase of 9% to $1.73B, Orthopaedics segment increase of 5% to $2.21B, Advanced Wound Management segment increase of 6% to $1.61B, United States of America segment increase of 8% to $2.98B, Other Established Markets segment increase of 14% to $1.14B.
Financials
Income Statement - All values are in GBP (M).
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
---|---|---|---|---|---|---|
Total Revenue | 5,549.00 | 5,215.00 | 5,212.00 | 4,560.00 | 5,138.00 | 4,904.00 |
Gross profit | 3,922.00 | 3,705.00 | 3,705.00 | 3,185.00 | 3,812.00 | 3,610.00 |
Operating Profit/Loss | 419.00 | 442.00 | 660.00 | 295.00 | 815.00 | 863.00 |
Profit Before Tax | 290.00 | 235.00 | 586.00 | 246.00 | 743.00 | 781.00 |
Profit After Tax | 263.00 | 223.00 | 524.00 | 448.00 | 600.00 | 663.00 |
Equity Holders of Parent Company | 263.00 | 223.00 | 524.00 | 448.00 | 600.00 | 663.00 |
Minority Interest | NIL | NIL | NIL | NIL | NIL | NIL |
Balance Sheet - All values are in GBP (M).
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
---|---|---|---|---|---|---|
Total Non-Current Assets | 5,957.00 | 6,110.00 | 6,496.00 | 6,348.00 | 6,080.00 | 4,982.00 |
Total Current Assets | 4,030.00 | 3,856.00 | 4,424.00 | 4,664.00 | 3,219.00 | 3,077.00 |
Total Assets | 9,987.00 | 9,966.00 | 10,920.00 | 11,012.00 | 9,299.00 | 8,059.00 |
Total Liabilities | 4,770.00 | 4,707.00 | 5,352.00 | 5,733.00 | 4,158.00 | 3,185.00 |
Total Net Assets | 5,217.00 | 5,259.00 | 5,568.00 | 5,279.00 | 5,141.00 | 4,874.00 |
Shareholders Funds | 5,217.00 | 5,259.00 | 5,568.00 | 5,279.00 | 5,141.00 | 4,874.00 |
Minority Interests | NIL | NIL | NIL | NIL | NIL | NIL |
Total Equity | 5,217.00 | 5,259.00 | 5,568.00 | 5,279.00 | 5,141.00 | 4,874.00 |
Outlook
Broker View
Data shown is based on the past 75 days of broker views.
ActionBrokers |
Strong Buy6 |
Buy5 |
Neutral6 |
Sell0 |
Strong Sell1 |
---|---|---|---|---|---|
Brokers | 6 | 5 | 6 | 0 | 1 |
Consensus |
ConsensusBuy |
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
Forecasts
Year | 2024 | 2025 | 2026 |
---|---|---|---|
Revenue | £5,831.97mn | £6,133.50mn | £6,462.05mn |
Pre-tax-Profit | £945.88mn | £1,105.06mn | £1,201.86mn |
EPS | £0.74p | £0.87p | £0.97p |
EPS Growth | -10.82% | 18.46% | 11.30% |
P/E | 13.93 | 11.85 | 10.58 |
PEG Ratio | -1.29 | 0.64 | 0.94 |
Dividend | 30.60p | 34.30p | 38.61p |
Yield | 0.00% | 0.00% | 0.00% |
Upgrades & Downgrades (Latest)
Date | Broker | Recommendation | Price | Old Target | New Target | Change |
---|---|---|---|---|---|---|
9th Feb 2024 | Barclays | Reiteration | 1093p | 0p | 1150p | Equal-weight |
30th Nov 2023 | JP Morgan Cazenove | Reiteration | 1023p | 0p | 1248p | Overweight |
30th Nov 2023 | Berenberg Bank | Reiteration | 1023p | 0p | 1500p | Buy |
30th Nov 2023 | Barclays | Reiteration | 1023p | 0p | 1150p | Equal-weight |
6th Nov 2023 | RBC Capital Markets | Reiteration | 984p | 1600p | 1500p | Outperform |
2nd Oct 2023 | Barclays | Reiteration | 998p | 0p | 1200p | Underweight |
20th Jul 2023 | JP Morgan Cazenove | Reiteration | 1199p | 0p | 0p | Neutral |
3rd Jul 2023 | JP Morgan Cazenove | Reiteration | 1195p | 0p | 1612p | Neutral |
15th Jun 2023 | Citigroup | Reiteration | 1251p | 0p | 0p | Buy |
16th May 2023 | Berenberg Bank | Reiteration | 1299p | 1400p | 1500p | Buy |
Time & Sales
All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.
Date | Time | Price | Volume | Type |
---|---|---|---|---|
28 Mar 2024 | 18:45 | 991.45 | 13,795 | Sell |
28 Mar 2024 | 18:45 | 991.45 | 4,546 | Sell |
28 Mar 2024 | 18:45 | 991.45 | 2,426 | Sell |
28 Mar 2024 | 18:45 | 991.45 | 36,784 | Sell |
28 Mar 2024 | 18:10 | 1,002.592 | 20,554 | Sell |
28 Mar 2024 | 18:10 | 1,000.672 | 19,919 | Sell |
28 Mar 2024 | 18:07 | 1,000.876 | 158,273 | Sell |
28 Mar 2024 | 18:07 | 1,005.734 | 18,885 | Sell |
28 Mar 2024 | 17:58 | 991.6 | 16,420 | Sell |
28 Mar 2024 | 17:58 | 995.588 | 189,038 | Sell |
28 Mar 2024 | 17:58 | 991.6 | 16,028 | Sell |
28 Mar 2024 | 17:57 | 991.6 | 2,073 | Sell |
28 Mar 2024 | 17:57 | 991.6 | 25,503 | Sell |
28 Mar 2024 | 17:57 | 991.6 | 42 | Sell |
28 Mar 2024 | 17:57 | 991.6 | 351 | Sell |
28 Mar 2024 | 17:57 | 991.6 | 2,545 | Sell |
28 Mar 2024 | 17:57 | 1,009.341 | 60,035 | Sell |
28 Mar 2024 | 17:47 | 1,006.494 | 147 | Sell |
28 Mar 2024 | 17:47 | 1,006.514 | 272 | Sell |
28 Mar 2024 | 17:41 | 1,005.8348 | 3,336 | Sell |
Selected data supplied by Thomson Reuters © View restrictions.